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Abstract
Background: Colorectal cancer (CRC) is the most common cancer and a leading cause of death worldwide.
Extracellular matrix (ECM) proteins regulate tumor growth and development in CRC. Elastin (ELN) is a component of
ECM proteins involved in the tumor microenvironment. However, the role of ELN in CRC remains unclear.
Methods: In this study, we analyzed ELN gene expression in tumors from CRC patients and adjacent non-tumor
colon tissues and healthy controls from two existing microarray datasets. ELN protein was measured in human
normal colon cells and colon cancer epithelial cells and tumor development was assessed in colon epithelial cells
cultured in medium with or without ELN peptide on plates coated with ELN recombinant protein. Control plates
were coated with PBS only.
Results: We found ELN gene expression was increased in tumors from CRC patients compared to adjacent non-
tumor tissues and healthy controls. ELN protein was increased in cancer cells compared to normal colon epithelial
cells. Transforming growth factor beta (TGF-β) was a key cytokine to induce production of ECM proteins, but it did
not induce ELN expression in colon cancer cells. Matrix metalloproteinase 9 (MMP9) gene expression was increased,
but that of MMP12 (elastase) did not change between CRC patients and control. Tissue inhibitor of
metalloproteinases 3 (TIMP3) gene expression was decreased in colon tissues from CRC patients compared to
healthy controls. However, MMP9, MMP12 and TIMP3 proteins were increased in colon cancer cells. ELN
recombinant protein increased proliferation and wound healing in colon cancer epithelial cells. This had further
increased in cancer cells incubated in plates coated with recombinant ELN coated plate and in culture media
containing ELN peptide. A potential mechanism was that ELN induced epithelial mesenchymal transition with
increased alpha-smooth muscle actin and vimentin proteins but decreased E-cadherin protein. Tumor necrosis
factor alpha (TNF) mRNA was also increased in CRC patients compared to controls. ELN recombinant protein
induced further increases in TNF protein in mouse bone marrow derived macrophages after lipopolysaccharide
stimulation.
Conclusions: These data suggest ELN regulates tumor development and the microenvironment in CRC.
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Background
Colon cancer, also known as colorectal cancer (CRC), is
the third most common cancer diagnosed in both men
and women, and it is the second cause of cancer mortal-
ity with more than 700,000 deaths worldwide [1]. The
exact cause of CRC remains unknown, however polyps
have been identified as major precursor to lesions of
CRC given approximately 95% of CRC patients have
these polyps in their colons [2]. Some other risk factors
have also contributed to the prevalence of CRC, includ-
ing age, cigarette smoke, heavy alcohol consumption,
lack of physical activity and genetic family history [3].
Current treatments for CRC aim to block cancer cell
growth and metastasis, but there are limited effects on
destruction of cancer cells due to the tumor microenvir-
onment in the colon. Therefore, surgery is still the most
common therapeutic approach for CRC patients.
Extracellular matrix (ECM) proteins play an important
role in regulating cancer cell behaviour and the micro-
environment whereby abnormal deposition of ECM re-
sults in tissue remodelling and cancer tumorigenesis [4].
ECM proteins are non-cellular structural macromolecules
which provide dynamic structural support for integrity
and elasticity in all tissues. However, dysregulation of
ECM proteins in cancer is characterized by altered tissue
structure and composition. Tumors are commonly associ-
ated with stiffening structure that mainly induced by high
ECM deposition compared to the surrounding tissue [5],
however some tumor cells must destroy the ECM struc-
ture in order to invade other tissues and metastasise dur-
ing the latter stages of cancer development [6]. Matrix
metalloproteinases (MMPs) are the main enzyme to cleave
ECM products, while MMPs associated with their inhib-
ition, tissue inhibitor of metalloproteinases (TIMPs),
maintain the level of ECM proteins in tissues [6].
Fibrous protein and proteoglycans are the two main
types of ECM proteins [5]. Collagen and elastin (ELN)
are fibrous proteins that provide structural integrity
and function of tissues. Collagen, a main component of
ECM protein provides resistance and support to tissues,
while ELN provides the characteristic elasticity proper-
ties in many soft tissues [7]. Abnormal level of ELN
have been observed in many fibrotic diseases, including
kidney [8], lung [9] and liver fibrosis [10]. Studies have
shown that fibrosis is a contributing factor in cancer
development, and is involved in early stages of CRC
[11]. The level of ELN in different cancers has been
identified, and an accumulation of ELN fibre is associ-
ated with the development of hepatocellular carcinoma
[12]. Increased degradation of ELN is found in human
breast cancer due to increased activity of MMPs [7].
However, the level of ELN in CRC has not been mea-
sured and the role of this molecule in CRC is not well
understood.
In this study, we hypothesize that ELN is a key ECM
protein regulating tumor growth and development in
CRC. We aimed to measure ELN gene expression and
its related MMP9, MMP12 and TIMP3 gene levels in
tumor from CRC patients compared to adjacent non-
tumor tissues and healthy controls in existing array data-
sets. We also validated the increased levels of MMPs
and TIMP3 proteins in colon cancer cells compared to
normal cells. Culture on plates coated with recombinant
ELN peptide and in media containing ELN peptide fur-
ther increases proliferation of colon cancer epithelial
cells and induces epithelial mesenchymal transition
(EMT). Lipopolysaccharide (LPS)-induced tumor necro-
sis factor (TNF) secretion by bone marrow derived mac-
rophages (BMDM) are increased after incubation with
ELN recombinant protein. Therefore, these data impli-
cate that ELN is a key protein in the tumor microenvir-
onment in CRC and targeting this molecule may help
understand the pathogenesis of this disease.
Methods
Gene expression in human CRC microarray dataset
Type I alpha I collagen (COL1A1), type III alpha I col-
lagen (COL3A1), ELN, MMP9, MMP12, TIMP3, TNF
gene expressions were from existing microarray data-
sets through Gene Expression Omnibus (GEO). The
data were analyzed using Bioconductor in R as previously
described [13, 14].
In GSE128449 dataset, gene microarray from colorec-
tal tissues were obtained from healthy controls (n = 5)
and CRC patients (n = 31) as shown in Additional file 1:
Table S1. Data was profiled by Agilent-014850 Whole
Human Genome Microarray 4x44K G4112F.
In GSE110224 dataset, 17 patients with no significant
age difference had been histologically confirmed with
CRC [15], and tissue specimens of tumor and adjacent
non-tumor tissues were collected during surgery. The
isolated RNA was previously profiled by Affymetrix Hu-
man Genome U133 Plus 2.0 array.
In GSE79462, colon tissues were obtained from resec-
tion of CRC patients and healthy controls, and colon
organoids were isolated as described previously [16, 17].
The colon organoid cultures were treated with 5 ng/ml
recombinant human TGF-β1 protein for 5 days. Total
RNA was extracted from cells and microarray data was
profiled by Affymetrix Human Genome U133 Plus 2.0
array as previously described [17].
The Benjamini-Hochberg method for adjusted P
value/false discovery rate (FDR) was used to analyze
differences between groups. Statistical significance was
set at FDR < 0.05. All target gene expression was calcu-
lated as log2 intensity robust multi-array average signals
(Log2 transformed intensity value) [18, 19].
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Cell culture
Normal human colon epithelial cells (FHC, CRL-1831,
ATCC, Manassas, VA, USA) were cultured with Dulbecco’s
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/
F12) supplemented with 10mM HEPES, 10 ng/ml cholera
toxin, 5 μg/ml insulin, 5 μg/ml transferrin, 100 ng/ml
hydrocortisone, 20 ng/ml recombinant epidermal growth
factor protein and 10% fetal bovine serum (FBS) at 37 °C
with 5% CO2.
Human recombinant ELN (10 μg/ml, E6902, Sigma-
Aldrich, St. Louis, USA) dissolved in sterile PBS was
used to coat cell culture plates overnight at room
temperature (RT). Control plates were coated with PBS
only [7]. Human colon cancer epithelial cells (Caco-2,
HTB-37, ATCC, Manassas, VA, USA) were seeded into
each well of 24- or 96-well plate and cultured in Eagle’s
Minimum Essential Medium (EMEM) containing 2.5
mM L-glutamine, 10 mM HEPES and 10% FBS at 37 °C
with 5% CO2. Some cells were cultured in EMEM media
with (or without) soluble human ELN peptide (10 μg/ml,
ab101300, Abcam, UK). All the cell lines have been au-
thenticated by PCR with short tandem repeat markers,
and mycoplasma contamination were checked by using
cell culture contamination detection kit (C7028, Thermo
Fisher Scientific, MA, USA). The cells were then har-
vested for cell proliferation and migration assays. mRNA
was obtained for qPCR and proteins were collected from
cell lysates for immunoblot.
Cell proliferation assay
Caco-2 cells (1 × 105 cells/well) were grown on 96-well
plates coated with (or without) human recombinant
ELN as well as treated with culture media with (or with-
out) human ELN peptide. Cell proliferation assays were
performed using MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide] (Sigma-Aldrich, Shanghai,
China). Briefly, cell media was changed to serum-free
EMDM media after centrifugation (1000 xg, 4 °C for 5
min). MTT was added to each well and incubated for 3
h at RT. MTT solvent was then added to cells and incu-
bated for 15 min with shaking. Optical density (OD) was
measured at a wavelength of 590 nm. A standard curve
was generated using OD values verses cell number based
on the known number of cell populations as previously
described [20]. The population of Caco-2 cells was
calculated after 6, 12, 24, and 48 h culture in media with
(or without) ELN peptide on plates coated with (or
without) ELN recombinant protein.
In vitro wound healing and migration assay
Cacao-2 cells (5 × 105 cells/well) were cultured on a 24-
well plate, and starved in serum free EMEM media for
16 h to minimize cell proliferation [21]. A straight line
across the centre of each well was scratched using a
p200 pipette tip. The cells were then gently washed by
three times in PBS to remove detached cells. Fresh serum
free EMEMmedia with (or without) ELN peptide was added
and the cells were incubated for a further 48 h at 37 °C with
5% CO2. Images were taken using a phase-contrast micro-
scope at 0, 6 and 12-h. The area of each scratch at each time
point was compared to the images from 0 h using ImageJ
software as previously described [22].
Protein extraction
Total proteins were extracted from cell lysate using radio
immunoprecipitation assay buffer (RIPA; Sigma-Aldrich,
St. Louis, USA), supplemented with protease and phos-
phatase inhibitors (Thermo Fisher Scientific, MA, USA).
Lysed cell samples were centrifuged (8000 xg, 10min,
4 °C) and supernatants were collected for protein assays.
Total protein concentrations from cell lysates were calcu-
lated based on a standard curve from known concentra-
tion of albumin using a Pierce bicinchoninic acid (BCA)
protein assay kit (Thermo Fisher Scientific, MA, USA)
according to the manufacturer’s instructions.
Immunoblot
Proteins from cell lysates were separated by electrophoresis
and transferred onto polyvinylidene difluoride (PVDF)
membranes. Membranes were blocked with 5% skim milk
for 2 h at RT, and then incubated with anti-elastin (1: 2000,
ab23747, Abcam, Cambridge, UK), anti-SMA (1:750,
ab5694, Abcam, Cambridge, UK), anti-vimentin (1:2000,
ab92547, Abcam, Cambridge, UK), E-cadherin (1: 2000,
3195, Cell signalling technology, USA) and anti-β-actin (1:
10,000, ab8226, Abcam, Cambridge, UK) at 4 °C overnight.
Blots were incubated with anti-rabbit or anti-mouse IgG
HRP conjugated antibodies (R&D System, MN, USA) at
RT for 2 h after TBS-Tween-20 wash (3 times, 10min).
Substrate (SuperSignal™ West Femto Maximum sensitivity
substrate, Thermo Fisher Scientific, MA, USA) was added
to the membrane and images of immunoblots were cap-
tured using a ChemiDoc MP System (Bio-Rad, Hercules,
USA). Some blots were cut based on molecular weight and
some blots were stripped only once for housekeeping pro-
tein. Densitometry analysis was performed relative to the
housekeeping protein β-actin using ImageJ (NIH, Bethesda,
USA) as previously described [23, 24].
Animals
Six female wild type C57Bl/6 mice aged 5–7 weeks
old were obtained from Animal Experimental Center
of Beijing Vital River Lab Animal Technology Co.
Ltd. (Beijing, China) and maintained at pathogen-free
facility in Experiment Center of Bengbu Medical Col-
lege. Mice were sacrificed at 10 weeks of age by cer-
vical dislocation for bone marrow derived macrophage
(BMDM) collection.
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BMDM
L929 cells were seeded into a 75-cm2 flask with 50 ml
DMEM media containing 10% FCS 1% L-glutamine and
cultured at 37 °C with 5% CO2 for 7 days. Supernatant
was collected and filtered (0.45 um) as L292-condition
media. Bone marrow was isolated from the hind legs of
mice by removing connective muscle tissue. The femur
and tibia were separated by cutting the joint and bone
marrow cells were collected by flushing the bone with 1
ml DMEM media twice (using a 3 ml syringe and 25-
gauge needle). The cells were then centrifuged (300 xg,
5 min), resuspended in L292-conditioned media and cul-
tured at 37 °C with 5% CO2. Bone marrow cells began to
differentiate into BMDMs attached to the flask after 7
days incubation as previously described [25].
Flow cytometry
Single cell suspensions were obtained from BMDM cell
culture. Cells were incubated with Fc block (BD Phar-
mingen, Franklin Lakes, USA) at 4 °C for 30 min and
stained with F4/80 (Conjugated with FITC, BD Pharmin-
gen, Franklin Lakes, USA) antibody at 4 °C for 1 h in the
dark. Cells were then enumerated by flow cytometric
analysis using a BD LSRFortessa™ flow cytometer with
FACSDiva software (BD Biosciences, Franklin Lakes,
USA). An anti-mouse Ig, k/Negative compBeads (552,843,
BD bioscience, US) was used for single color control and
negative control. BMDMs were stained with single color
and unstained cells were also used as controls for analysis.
Data was analysed using FlowJo software (BD Biosciences,
Franklin Lakes, USA) as previously described [26, 27].
Enzyme-linked immunosorbent assay (ELISA)
The concentration of TNF in mouse BMDMs was deter-
mined using DuoSet ELISA kits (DY410, R&D systems,
Minneapolis, USA) according to the manufacturer’s
instructions. The standard curve in this kit ranges from
31.3 to 2000 pg/ml. Each sample, including standards are
triplicated and only coefficient of variation less than 6 were
used in this study. The concentration of TNF in BMDMs
was normalized to the total protein concentration.
Statistical analysis
Results are presented as mean ± standard error of the
mean (SEM). Each in vitro experiment was performed in
triplicate and repeated in three or four independent ex-
periments. Unpaired student t-Tests were used to com-
pare two groups in existing dataset analysis and cell
culture experiments. A one-way analysis of variance
(ANOVA) with Bonferroni comparisons was used to
compare between multiple groups. All statistical analyses
were performed using GraphPad Prism Software (San
Diego, CA, USA).
Results
Collagen and ELN are increased in patients with CRC
Collagen is the most abundant ECM protein and previ-
ous studies have shown a correlation of increased colla-
gen expression with CRC [28]. To confirm this finding,
we assessed COL1A1 expression, the most abundant
molecule of the collagen family, in tumor tissues from
CRC patients and colon tissues from healthy controls
using an existing dataset (GSE128449). COL1A1 expres-
sion was significantly increased in tumors from CRC pa-
tients compared to colon tissues from healthy controls
(P < 0.003, Additional file 1: Fig. S1A). COL3A1 is an-
other important component in the collagen family, and
COL3A1 expression was also significantly increased in
CRC patients compared to healthy controls (P < 0.03,
Additional file 1: Fig. S1B). To examine whether the
increased collagen was associated with tumors develop-
ment, we next assessed the level of collagen mRNA
expression in tumors and adjacent non-tumor colon tis-
sues from the same CRC patients (GSE110224). COL1A1
and COL3A1 mRNA expression was significantly in-
creased in tumor tissue compared to adjacent non-
tumor tissues in colons from CRC patients (P < 0.0001
and P < 0.03, Additional file 1: Fig. S1C and D).
We then assessed the level of ELN in CRC patients
using the same microarray datasets. We found that ELN
mRNA expression was significantly increased in tumor
tissues from CRC patients compared to those from
healthy controls (P = 0.0022, Fig. 1a). There was also sig-
nificantly increased ELN mRNA expression in tumors
from CRC patients compared to adjacent non-tumor tis-
sues (P = 0.0363, Fig. 1b). We next assessed the level of
ELN protein in human colon cancer epithelial cells com-
pare to normal colon epithelial cells (Fig. 1c, Additional
file 1: Fig. S2). ELN protein was significantly increased in
cancer cells after 48 h incubation compared to normal
colon cells, although ELN protein was not changed at
the early time point (Fig. 1d). These results indicate that
increased ELN is associated with tumor development in
CRC patients.
TGF-β does not affect ELN, but MMP9 and TIMP3 are
associated with increased ELN mRNA in CRC development
Previous studies have shown that TGF-β is a main
growth factor to induce the productions of ECM pro-
teins in cells [29]. Given increased ELN was found in
CRC patients, we then determined whether TGF-β in-
duced ELN expression in colon organoids from CRC pa-
tients and healthy controls according to an existing
dataset (GSE79462) [17]. TGF-β challenge did not affect
ELN mRNA level in colon organoids from CRC patients
or controls (P = 0.329, Fig. 2a). To further explore the
mechanism of increased ELN in CRC, we then assessed
the level of MMP expression in colon tissues from CRC
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patients and healthy controls. MMP12 is the main
enzyme to catalyse ELN, and we found that MMP12
expression was not changed between tumors from CRC
patients and controls (P = 0.2426, Fig. 2b). However,
MMP9 gene expression was increased in tumors from
CRC patients compared to colons in healthy controls
(P = 0.0318, Fig. 2c). TIMP3 is an inhibitor of MMPs
and its gene expression was significantly decreased in
tumor tissues compared to controls (P = 0.0003, Fig. 2d).
We then assessed MMPs and TIMP3 expression in
tumors and adjacent non-tumor colon tissue in CRC pa-
tients, MMP12 (P = 0.001, Fig. 2e), MMP9 (P = 0.0006,
Fig. 3f) and TIMP3 (P = 0.0421, Fig. 2g) mRNA expression
was significantly increased in tumors tissue compared to
adjacent non-tumor tissue from CRC patients.
MMP9, MMP12 and TIMP3 protein is increased in colon
cancer cells
Given abnormal levels of MMP9, MMP12 and TIMP3
mRNA expression in tumors from CRC patients and
controls, we next measured the level of the MMPs and
TIMP3 proteins in human colon cancer epithelial cells
compared to normal colon cells by immunoblot (Fig. 3a,
Additional file 1: Fig. S3). ELN proteins had the high
level in cancer cells after 48 h culture compared to nor-
mal colon epithelial cells (Fig. 1d). Thus, we chose this
time point to measure the protein level of MMPs. Both
MMP9 and MMP12 proteins were increased in colon can-
cer epithelial cells compared to controls (Fig. 3b and c),
with MMP12 proteins having more than 2-fold increase,
while MMP9 proteins had a 1.3-fold increase in cancer
cells compared to normal cells. TIMP3 protein was also
measured in cancer and normal colon epithelial cells.
Colon cancer epithelial cells had higher levels of TIMP3
protein than normal colon epithelial cells (Fig. 3d).
ELN induces colon epithelial cancer cell migration and
proliferation
To investigate the role ELN plays in regulating tumor
development in CRC, we seeded human colon cancer
epithelial cells onto culture plates coated with (or with-
out) recombinant ELN protein for 48 h. Cell prolifera-
tion was measured by MTT after 6, 12, 24, and 48 h.
Cancer cell number were not changed after 6 h culture,
but significantly increased after 12 h incubation with
ELN recombinant protein compared to controls (Fig. 4a).
There was a further increase in cell proliferation after 24
and 48 h incubation with ELN recombinant protein
compared to controls. To further explore the role of
ELN in colon tumor growth, we seeded human colon
cancer epithelial cells onto plates coated with ELN
recombinant protein and incubated in medium with
Fig. 1 ELN mRNA expression is increased in colorectal cancer (CRC) patients, and ELN protein is increased in colon cancer epithelial cells. a ELN
gene expression was analyzed from colon tissues from healthy controls (n = 5) and CRC patients (n = 31) based on a GSE128449 dataset. b ELN
gene expression was analyzed from colon tissues from tumor and adjacent non-tumor tissues from the same CRC patients (n = 17) according to a
GSE110224 dataset. Colon cancer epithelial cells and normal colon epithelial cells were cultured. c ELN protein was assessed in cell lysates after
24 and 48 h incubation by immunoblot, and d fold change of densitometry normalized to β-actin, n = 4. Results are mean ± SEM. *P < 0.05
compared to normal colon epithelial cells
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(or without) ELN peptide. Cell numbers further in-
creased in plates coated with ELN and media con-
taining ELN peptide compared to cells cultured on
plates coated with ELN alone. We next determined
whether ELN regulates cancer cell migration by per-
forming a wound healing assay (Fig. 4b). ELN re-
combinant protein increased cancer cell growth and
reduced wound area after 6 h incubation compared
to PBS controls. Colon cancer cell migration had further in-
creased after 6 h incubation onto plates coated with recom-
binant ELN as well as in media containing ELN peptide.
The wound area had recovered after 12 h incubation in
plates coated with ELN recombinant protein in plates
coated with ELN and media containing ELN peptide
(Fig. 4c). This indicates ELN induces human colon
epithelial cell growth and migration.
ELN induced epithelial-mesenchymal transition (EMT) in
human epithelial cancer cells
EMT is a key process to induce cancer epithelial cell mi-
gration and invasion [30]. To further investigate the role
of ELN in the regulation of tumor development in CRC,
we measured EMT markers alpha smooth muscle actin
(α-SMA) and vimentin (VIM) [31] in human colon cancer
epithelial cells cultured on plates collated with (or with-
out) ELN recombinant protein and with (or without)
media containing ELN peptide for 48 h by immunoblot
(Fig. 5a, Additional file 1: Fig. S4). The level of α-SMA
protein in colon cancer epithelial cells had increased
coated plate compared to controls (Fig. 5b). In addition,
the level of VIM protein was also significantly increased in
cancer cells after incubation with ELN protein and peptide
compared to controls (Fig. 5c), indicating elastin proteins
Fig. 2 ELN mRNA is not changed, but abnormal levels of MMP12, MMP9 and TIMP3 mRNA expression are found in tumor from CRC patients
compared to adjacent non-tumor colon tissues and healthy controls. a Colon organoid were isolated from tumor tissues in CRC patients and
healthy controls. The organoids were stimulated with TGF-β for 5 days, and ELN mRNA expression was measured from microarray data based on
a GSE79462 dataset (n = 5–6). MMP12 (b), MMP9 (c) and TIMP3 (d) gene expression was analyzed from colon tissues from healthy controls (n = 5)
and CRC patients (n = 31) based on a GSE128449 dataset. MMP12 (e), MMP9 (f) and TIMP3 (g) gene expression was analyzed from colon tissues
from tumor and adjacent non-tumor tissues from the same CRC patients (n = 17) according to a GSE110224 dataset. Results are mean ± SEM
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induced EMT in colon epithelial cancer cells. E-cadherin
(a marker of epithelial cells) was also measured in colon
cancer epithelial cells incubated on plates coated with (or
without) recombinant ELN and with (or without) media
containing ELN peptide for 48 h. E-cadherin proteins were
significantly decreased in colon cancer epithelial cells after
48 h on plates coated with recombinant ELN alone. E-
cadherin proteins had a further decreased in cells follow-
ing culture on plates coated with recombinant ELN as well
as in media containing ELN peptide.
TNF gene expression is increased in CRC patients and ELN
induces bone marrow derived macrophages (BMDM) to
secrete TNF
Inflammation is a key factor in inducing tumor develop-
ment, and cytokines, such as TNF involved in chronic in-
flammation contributed to this microenvironment [32].
We found that TNF mRNA expression was significantly
increased in colon tumor tissues from CRC patients com-
pared to healthy controls (P = 0.0498, Fig. 6a). TNF mRNA
expression was also increased in tumors from CRC pa-
tients compared to adjacent non-tumor tissues in colons
from the same patients (P = 0.034, Fig. 6b). Macrophages
are the main cell types secreting TNF and therefore in-
volved in tumor formation in CRC [33]. To further under-
stand the role of ELN in regulating tumor development in
CRC, we isolated BMDM from mice with over 96% purity
(Fig. 6c). Lipopolysaccharide (LPS) is a gram-negative bac-
teria antigen involved in inflammation and colorectal can-
cer progression. BMDMs were cultured with recombinant
ELN proteins with (or without) LPS challenge. Cell lysates
were collected, and TNF protein was measured after 24 h
and 48 h incubation by ELISA. ELN recombinant protein
induced TNF protein secretion after 48 h compared to
controls (Fig. 6d). However, ELN treated cells had further
increased TNF protein secretion after LPS challenge com-
pared to LPS only. This indicates that ELN protein acti-
vates macrophages to release TNF thereby changing the
microenvironment in local tissues.
Discussion
ECM proteins are important macromolecules contribut-
ing to the microenvironment in tumor development in
many cancers, including CRC. ELN is a key component
of the ECM family and plays critical roles in elasticity
properties in soft tissues and may contribute to tumor
Fig. 3 MMP9, MMP12 and TIMP3 proteins are increased in colon cancer epithelial cells compared to normal colon cells. Colon cancer epithelial
cells (Caco-2) and normal colon epithelial cells were cultured. a MMP12, MMP9 and TIMP3 protein was assessed in cell lysates after 48 h
incubation by immunoblot. Fold change of densitometry of MMP12 (b), MMP9 (c) and TIMP3 (d) normalized to β-actin, n = 4. Results are mean ± SEM.
*P < 0.05, **P < 0.01 compared to normal colon epithelial cells. Uncropped blots were shown in Additional file 1: Fig. S3
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formation. Previous studies have shown that ELN pro-
motes human breast cancer cell invasiveness [7], indicat-
ing a potential role of ELN in cancer cell migration.
However, the level of ELN in CRC has not been mea-
sured and the role of this molecule in CRC is not fully
understood. We are the first to measure ELN gene ex-
pression in CRC from two existing microarray datasets.
ELN mRNA expression is increased in tumors from
CRC patients compared to normal colon tissues from
healthy controls, and in tumor tissue compared to
adjacent non-tumor colon tissues from the same CRC
patients. We have also found increased ELN protein in
cancer cells compared to normal colon epithelial cells.
MMP12 gene expression is not changed, but MMP9
mRNA expression is increased in tumor from CRC pa-
tients compared to adjacent non-tumor tissues and con-
trols. TIMP3 gene decreased in CRC patients compared
to controls and slightly increased in tumor tissues com-
pared to adjacent none-tumor tissues. The protein levels
of MMP12, MMP9 and TIMP3 are increased in cancer
cells compared to controls after 48 h culture. In this
study, we are the first to show that ELN recombinant
protein further induced proliferation and migration of
human colon cancer epithelial cells. The ELN recombin-
ant protein also induces α-SMA and VIM proteins, but
reduces E-cadherin in colon cancer epithelial cells.
Chronic inflammation is also involved in CRC and we
show that TNF gene expression is increased in CRC
patients. LPS challenge increased TNF protein levels in
BMDM and this was further increased after incubation
with ELN recombinant protein.
Changes to ECM deposition in colon cell has contrib-
uted to the tumor microenvironment and ECM stiffen-
ing that is associated with tumor progression. Collagen
is the most abundant protein in the ECM and increased
deposition of collagen contributes to tissue remodelling
and tumor formation. Previous studies have shown that
collagen proteins are increased in CRC patients [34].
COL1A1 and COL3A1 are main two molecules in the
collagen family, and increased COL1A1 and COL3A1
ratio induces tissue stiffening [35]. Our results are con-
sistent with previous studies that gene expression of
these two molecules is increased in CRC patients, and
tumor tissues have more collagen expression than adja-
cent non-tumor tissues.
Increased ELN mRNA expression is found in tumors
from CRC patients compared to non-tumor tissue and
healthy controls. ELN proteins are also increased in can-
cer cells compared to normal colon epithelial cells. To
understand the mechanism of increased ELN in CRC,
we measure ELN gene expression in cancer cells after
TGF-β stimulation. TGF-β is a fibrotic cytokine that
Fig. 4 ELN increases human colon cancer epithelial cell proliferation and invasion. Human colon cancer epithelial cells (Caco-2) were seeded
onto plates coated with recombinant ELN protein and cultured in medium with (or without) ELN peptide. Control plates were coated with PBS
only. a Cell proliferation was assessed after 6, 12, 24 and 48 h incubation by MTT assay. b A straight scratch was performed in each well and
cancer cells invasion and migration were assessed by wound healing. c Wound area was assessed by measuring the wound closure size after 6
and 12 h post scratch, scale bar is 200 μm. n = 4. Results are mean ± SEM. *P < 0.05, ***P < 0.001 compared to cells cultured in normal medium on
control plates. ††† < 0.001, compared to cells cultured in medium contain ELN peptide on control plates. #P < 0.05 compared to cells cultured in
normal medium on ELN coated plates
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induces ECM proteins in many diseases [24]. However,
the level of ELN gene expression does not change be-
tween cells treated with TGF-β recombinant protein and
controls, indicating TGF-β is not involved in the induc-
tion of ELN expression in CRC. MMPs and TIMPs are
the main enzymes involved in maintaining ECM levels,
including ELN. MMP12 gene expression is not changed
between tumors from CRC patients and controls. TIMP3
gene expression decreased in tumor tissue in CRC
patients compared to healthy control, but its levels are
increased in tumors compared to adjacent non-tumor
tissues. However, the protein levels of MMP9, MMP12
and TIMP3 are increased in cancer cells. Dysregulation
of MMP gene expression and protein levels may not be
able to explain the increased ELN level in tumor tissues
from CRC patients. The enzyme activity of MMPs may
need to be further explored. The levels and roles of
MMPs and TIMPs are diverse during cancer develop-
ment. There are also many factors affecting MMP ex-
pression in the tumor microenvironment, including the
types of cancer cells and surrounding stromal cells [36].
In addition, the role of MMPs may switch from stimula-
tion of cancer cell growth to protection at different
stages during cancer progression [37, 38]. This may par-
tially explain why the gene and protein levels of MMP9
and MMP12 are different in CRC patients.
ELN was originally identified as an adhesion mol-
ecule in many tissues that are involved in cell-to-cell
or cell-to-ECM interaction. The role of ELN in tumor
development and metastasis has not been fully
understood. Previous studies show that ELN rapidly
binds to lung carcinoma and melanoma cells, indicat-
ing ELN has a high metastatic capacity [39]. In
addition, tumor cell invasion is commonly facilitated
within ELN rich pulmonary tissue [40]. We have
shown here that ELN recombinant protein increases
proliferation and invasion of human colon cancer
epithelial cells, indicating ELN plays an important
role in regulating cancer cell adhesion, migration and
invasion. While the mechanisms of ELN induced can-
cer cell migration remain unclear, EMT is an import-
ant process in tumor development and many ECM
proteins have been identified to induce EMT. Previ-
ous studies have shown that COL1A1 promotes air-
way epithelial cells to develop a mesenchymal cell
phenotype in lung cancer [41]. A potential
Fig. 5 ELN induces epithelial mesenchymal transition (EMT) in human colon cancer epithelial cells. Human colon cancer epithelial cells (Caco-2)
were seeded onto plates coated with recombinant elastin proteins. Control plates were coated with PBS only. Cells were cultured in medium
with (or without) ELN peptide for 48 h a Total protein were collected from cell lysates and α-SMA, vimentin (VIM) and E-cadherin proteins were
assessed by immunoblot. Fold change of densitometry of b α-SMA c VIM and d E-cadherin were normalized to β-actin. n = 4, Results are mean ±
SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared to cells cultured in normal media on control plates. ††† < 0.001, †††† < 0.0001
compared to cells cultured in medium containing ELN peptide on control plates. #P < 0.05, ##P < 0.01, ###P < 0.001 compared to cell cultured in
normal medium on ELN coated plates. Uncropped blots were shown in Additional file 1: Fig. S4
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relationship between ELN and EMT has been identi-
fied in organ fibrosis [42] and bronchopulmonary
dysplasia [43]. ELN and collagen together may be as-
sociated with EMT in non-small cell lung cancer
[44]. In this study, we have shown that human colon
cancer epithelial cells lose their epithelial marker, but
expressed mesenchymal markers after incubation
with ELN recombinant protein. Therefore, a potential
mechanism is that ELN induces the EMT process in
colon tissues and increases tumor cell proliferation
and invasion. The use of ELN functional peptide in
hydrogel assays may be used to provide a 3D culture
system, however the lack of commercial material
limits this work. In this study, we cultured cancer
cells in media containing ELN peptide on plates
coated with ELN recombinant protein to maximize
the ELN rich environment in cancer cells.
Chronic inflammation, a main factor of the tumor
microenvironment induces cancer risk in colon tissues,
and immune cells affect tumor development through
cytokines, chemokines and growth factors [32]. Previous
studies demonstrate that tumor-associated macrophages
express high level of proinflammatory cytokines, such as
TNF to promote tumor growth and invasion [45, 46]. We
have shown here that ELN recombinant protein induces
macrophages to secrete TNF. Infection also elevates the
risk of cancer development in CRC, and LPS from gram
negative bacteria has been identified to contribute to can-
cer metastasis in CRC [47]. LPS challenge increased mac-
rophages to secrete TNF products, and ELN recombinant
protein further increased TNF after LPS challenge. In
addition, inflammation was thought to be a driver of ECM
production and remodelling. However, recent studies have
shown that inflammation and abnormal deposition of
ECM proteins are two independent pathways. We have
previously shown that ECM proteins regulate inflamma-
tion in chronic diseases [23, 26]. Here, we have demon-
strated that ELN induces macrophages involved in
inflammation. This provides further evidence that ECM
proteins regulate inflammation.
Fig. 6 TNF mRNA is increased in CRC patients and ELN recombinant protein increases TNF protein from bone marrow derived macrophages
(BMDM) after LPS challenge. a TNF gene expression was analyzed from colon tissues from healthy controls (n = 5) and CRC patients (n = 31)
based on a GSE128449 dataset. b TNF gene expression was analyzed from colon tissues from tumor and adjacent non-tumor tissues from the
same CRC patients (n = 17) according to a GSE110224 dataset. c BMDM were isolated from mice and the purity of macrophages were assessed
by flow cytometry. d BMDM were cultured on plates coated with recombinant ELN protein, and control plates were coated with PBS only. BMDM
cell lysates were collected 24 and 48 h after LPS challenge, and TNF proteins measured by ELISA. n = 6. Results are mean ± SEM. **P < 0.01, ***P <
0.001 compared to control plates. #P < 0.05 compared to plates coated with LPS only
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Conclusions
Taken together, our data show that ELN plays an
important role in regulating tumor cell proliferation and
invasion in CRC. Identification of ELN responsible for
CRC may provide an opportunity to develop a new
therapeutic approach and exert a major impact on im-
proving the outcome of CRC patients.
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